Oral antibiotic therapy improves fat absorption in cystic fibrosis patients with small intestine bacterial overgrowth

Journal of Cystic Fibrosis

Volumn 10, Issue 6, 2011, Pages 418-421

  Lisowska, Aleksandra ^a   Pogorzelski, Andrzej ^b   Oracz, Grzegorz ^c   Siuda, Katarzyna ^a   Skorupa, Wojciech ^d   Rachel, Marta ^e,f   Cofta, Szczepan ^a   Piorunek, Tomasz ^a   Walkowiak, Jarosław ^a,g  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b National Institute for Tuberculosis and Lung Diseases   (Poland)

^c CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^d NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^e UNIVERSITY OF RZESZÓW   (Poland)

^f Regional Hospital Rzeszow   (Poland)

^g POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

Author keywords

Antibiotic therapy; Cystic fibrosis; Fat digestion and absorption; Small intestine bacterial overgrowth; Stable isotope breath test

Indexed keywords

AMIKACIN; CARBON 13; CEFTAZIDIME; CIPROFLOXACIN; TRIACYLGLYCEROL;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BREATH ANALYSIS; CHILD; CLINICAL ARTICLE; CYSTIC FIBROSIS; DISEASE EXACERBATION; FEMALE; HUMAN; HYDROGEN BREATH TEST; LIPID ABSORPTION; MALE; SCHOOL CHILD; SMALL INTESTINE BACTERIAL OVERGROWTH; SMALL INTESTINE DISEASE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; DIETARY FATS; FEMALE; HUMANS; INTESTINAL ABSORPTION; INTESTINE, SMALL; MALE; YOUNG ADULT;

EID: 81455131709     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2011.06.008     Document Type: Article

References (12)

1. Lewindon P.J., Robb T.A., Moore D.J., Davidson G.P., Martin A.J. Bowel dysfunction in cystic fibrosis: importance of breath testing. J Pediatr Child Health 1998, 34:79-82.
2. Fridge J.L., Conrad C., Gerson L., Castillo R.O., Cox K. Risk factors for small bowel bacterial overgrowth in cystic fibrosis. J Pediatr Gastroenterol Nutr 2007, 44:212-218.
3. Di Stefano M., Miceli E., Missanelli A., Corazza G.R. Treatment of small intestine bacterial overgrowth. Eur Rev Med Pharmacol Sci 2005, 9:217-222.
4. Borowitz D., Durie P.R., Clarke L.L., Werlin S.L., Taylor C.J., Semler J., et al. Gastrointestinal outcomes and confounders in cystic fibrosis. J Pediatr Gastroenterol Nutr 2005, 41:273-285.
5. Gregg C.R. Enteric bacterial flora and bacterial overgrowth syndrome. Semin Gastrointest Dis 2002, 13:200-209.
6. Norkina O., Kaur S., Ziemer D., De Lisle R.C. Inflammation of the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2004, 286:G1032-G1041.
7. Norkina O., Burnett D.G., De Lisle R.C. Bacterial overgrowth in cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun 2004, 72:6040-6049.
8. Lisowska A., Pogorzelski A., Oracz G., Skorupa W., Cofta S., Socha J., et al. Small intestine bacterial overgrowth and fat digestion and absorption in cystic fibrosis patients. Acta Sci Pol Technol Aliment 2010, 9:477-483.
9. Walkowiak J., Nousia-Arvanitakis S., Henker J., Stern M., Sinaasappel M., Dodge J.A. Indirect pancreatic function tests in children. J Pediatr Gastroenterol Nutr 2005, 40:107-114.
10. Walkowiak J. Assessment of maldigestion in cystic fibrosis. J Pediatr 2004, 145:285-287.
11. Reilly J.J., Evans T.J., Wilkinson J., Paton J.Y. Adequacy of clinical formulae for estimation of energy requirements in children with cystic fibrosis. Arch Dis Child 1999, 81:120-124.
12. Lisowska A., Pogorzelski A., Oracz G., Skorupa W., Cofta S., Szydłowski J., et al. No major effect of antibiotic therapy on fat digestion and absorption in cystic fibrosis. Acta Biochim Pol 2010, PMID: 21738905 [2011 Jul 7, Electronic publication ahead of print].